Prelude Therapeutics Incorporated (PRLD) vs Entrada Therapeutics, Inc. (TRDA)
A side-by-side comparison of Prelude Therapeutics Incorporated and Entrada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PRLD
Prelude Therapeutics Incorporated
$3.79HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
TRDA
Entrada Therapeutics, Inc.
$5.40HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — PRLD vs TRDA
growth of $100 · dividends reinvested · last 5yPRLD -78.6% (-26.5%/yr)TRDA -77.1% (-25.5%/yr)TRDA compounded faster over this window
PRLD TRDA
PRLD vs TRDA: by the numbers
- •PRLD is the larger company ($216M vs $210M market cap).
- •Both run net losses; PRLD's is the smaller (-269.75% vs -3537.73% net margin).
Metrics side by side
Valuation
| Metric | PRLD | TRDA |
|---|---|---|
| P/S ratio | 9.61 | 44.75 |
| P/B ratio | 1.61 | 0.90 |
Profitability
| Metric | PRLD | TRDA |
|---|---|---|
| Gross margin | 85.91% | 83.89% |
| Operating margin | -861.33% | -613.66% |
| Net margin | -269.75% | -3537.73% |
| ROE | -45.23% | -71.02% |
| ROIC | -43.74% | -63.61% |
Growth (annualized)
| Metric | PRLD | TRDA |
|---|---|---|
| Total return CAGR (5Y) | -33.98% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.